menu
    • menu
    [{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium Chloride, Sr-89","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Strontium Chloride, Sr-89","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/ isoSolutions"}]

    Find Clinical Drug Pipeline Developments & Deals for STRONTIUM CHLORIDE SR-89

    Menu

    STRONTIUM CHLORIDE SR-89

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium Chloride, Sr-89

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

                            Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                            Brand Name : Metastron

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 10, 2021

                            Lead Product(s) : Strontium Chloride, Sr-89

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : isoSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Q BioMed

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strontium Chloride, Sr-89

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Midd...

                            Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

                            Brand Name : Metastron

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Strontium Chloride, Sr-89

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Clionix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth